Does Bivalent RSV Prefusion F Vaccine prevent RSV-associated lower respiratory tract illness and acute respiratory illness in adults ≥60 years of age?
adults (≥60 years of age)
Bivalent RSV Prefusion F Vaccine (RSVpreF)
RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illnesshard clinical
The bivalent RSVpreF vaccine prevents RSV-associated lower and acute respiratory tract illness in older adults without evident safety concerns.
RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns. (Funded by Pfizer; RENOIR ClinicalTrials.gov number, NCT05035212; EudraCT number, 2021-003693-31.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Edward E. Walsh
University of Rochester Medical Center
Gonzalo Pérez Marc
Johns Hopkins University
Agnieszka Zareba
Pfizer (United States)
New England Journal of Medicine
Utrecht University
University Medical Center Utrecht
Pfizer (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Walsh et al. (Wed,) studied this question.
synapsesocial.com/papers/69d89b7d8cb8f39931ae35e0 — DOI: https://doi.org/10.1056/nejmoa2213836